Acorda Therapeutics (ACOR) Stock Forecast, Price & News

Acorda Therapeutics' stock was trading at $15.3340 at the start of the year. Since then, ACOR shares have decreased by 2.6% and is now trading at $14.93.
View the best growth stocks for 2023 here.

Acorda Therapeutics saw a increase in short interest in September. As of September 15th, there was short interest totaling 13,300 shares, an increase of 95.6% from the August 31st total of 6,800 shares. Based on an average daily volume of 8,800 shares, the days-to-cover ratio is currently 1.5 days. Currently, 1.1% of the shares of the company are short sold.
View Acorda Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our ACOR earnings forecast.

Acorda Therapeutics, Inc. (NASDAQ:ACOR) released its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($7.55) earnings per share for the quarter. The biopharmaceutical company earned $29.68 million during the quarter. Acorda Therapeutics had a negative net margin of 17.89% and a negative trailing twelve-month return on equity of 26.63%.

Acorda Therapeutics's stock reverse split on Monday, June 5th 2023. The 1-20 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

39 employees have rated Acorda Therapeutics Chief Executive Officer Ron Cohen on Glassdoor.com. Ron Cohen has an approval rating of 55% among the company's employees. This puts Ron Cohen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), InterDigital (IDCC), Nektar Therapeutics (NKTR), Rigel Pharmaceuticals (RIGL), Novan (NOVN), SCYNEXIS (SCYX), Acasti Pharma (ACST) and Applied Materials (AMAT).

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

Acorda Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Davidson Kempner Capital Management LP (0.00%), Renaissance Technologies LLC (3.73%), Acadian Asset Management LLC (2.80%), BlackRock Inc. (0.56%) and Simplex Trading LLC (0.00%).
View institutional ownership trends.

Shares of ACOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACOR stock can currently be purchased for approximately $14.93.

Acorda Therapeutics (NASDAQ:ACOR) has a market capitalization of $18.51 million and generates $118.57 million in revenue each year. The biopharmaceutical company earns $-65,920,000.00 in net income (profit) each year or ($21.35) on an earnings per share basis.

The company employs 111 workers across the globe.

Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The official website for the company is www.acorda.com. The biopharmaceutical company can be reached via phone at (914) 347-4300 or via fax at 914-347-4560.